Huachuang Capital | Kekai Life Sciences' TAVR System Approved, Pioneering a New Path for Domestic Innovation

Source: Huachuang Capital

Kokai (Nantong) Life Sciences Co., Ltd. was established in September 2018. It is a high-end biopharmaceutical technology enterprise that focuses on the research, development, production, and sales of medical devices in the field of structural heart disease, developing systematic solutions for valve diseases targeting different populations, needs, and scenarios.

The company's technical team is primarily composed of returned R&D personnel from the United States and Germany. With years of development and research experience in the cardiac medical field, their technical expertise is among the leading in China and is synchronized with the most advanced frontier technologies in global cardiac medicine treatment.

On February 9, 2026, the National Medical Products Administration approved the marketing of the transcatheter aortic valve system developed by Kokai (Nantong) Life Sciences Co., Ltd. This news has drawn significant attention within the industry, not because it is the "first domestically produced TAVR" – in fact, domestically produced self-expanding TAVRs have already been widely used in the field of aortic valve stenosis – but because the product focuses on a long-neglected and technically challenging patient group: high-risk surgical patients with pure aortic regurgitation (pure AR).

These patients' heart valves lack calcified anchor points, making it difficult for traditional TAVR devices to be securely implanted, and they are often excluded from interventional treatment. The product recently approved for Kokai Life Sciences was specifically designed to address this clinical challenge.

01

Focus on "Non-Calcified Regurgitation," Tackling Global Technical Challenges

Aortic valve disease is mainly divided into two categories: Stenosis (AS) and Regurgitation (AR). Currently, mainstream TAVR products target severe aortic stenosis and rely on calcified structures for valve anchoring.

However, patients with pure aortic regurgitation typically present with non-calcified annuli, root dilation, and anatomical instability. Traditional self-expanding or balloon-expandable valves are prone to displacement or leakage, leading to high surgical risks and low success rates. Globally, only a few exploratory devices have entered clinical trials, and there is still no mature commercial solution available.

Kokai's PIONEER system was developed precisely to address this pain point:

Adopting a three-dimensional adjustable bending delivery system to achieve precise positioning;

Stent design enhances radial support and axial stability, suitable for non-calcified anatomy;

Optimize dimensions and release logic based on the characteristics of the aortic root in Chinese patients.

According to publicly available clinical data, the device success rate and 30-day survival rate in AR patients during its early trials reached the level of similar international studies, offering new possibilities for this "treatment blind spot."

02

Team Focuses on Structural Heart Disease, Pursues Differentiated Innovation Path

Kokai Life Sciences' core team has deep积累 in the cardiovascular intervention field and has participated in the development of multiple TAVR and TMVR projects both in China and internationally. Since its establishment, the company has chosen to avoid the highly competitive AS track, instead focusing on the high-risk, long-cycle细分方向 of AR.

This strategy may seem "risky," but it is actually based on a profound insight into clinical needs — the acceleration of aging in China, with the prevalence of AR increasing annually, especially significant in the population over 75 years old. Moreover, existing surgical procedures pose extremely high risks for elderly patients with multiple comorbidities, creating an urgent need for minimally invasive alternatives.

Locating the headquarters in Nantong also reflects practical considerations: leveraging the Yangtze River Delta industrial chain, balancing R&D efficiency with cost control, and providing support for long-term investment.

03

Not "from 0 to 1," but "from difficult to feasible"

It needs to be clarified that domestically produced TAVR has long achieved breakthroughs in the field of aortic valve stenosis. The approval of Kokai (Nantong) Life Sciences Co., Ltd. does not "fill the gap in domestically produced TAVR" but rather expands the indications boundary of domestically produced TAVR.

This precisely represents a new phase of innovation in China's medical device industry: moving from "being able to do" to "daring to do what others haven't," and progressing from "following" to "defining new scenarios."

In the future, as this product enters real-world applications, its long-term durability, complication management, and the cultivation of doctors' operational habits will become critical tests. But at the very least, it has opened the door to interventional treatment for some patients who were previously considered "untreatable."

04

Policy and Clinical Practice Jointly Drive "Precision Innovation"

In recent years, the National Medical Products Administration (NMPA) has provided review support for innovative devices with clear clinical value. The approval of Kokai Life Sciences' product through the innovation channel also reflects the regulatory encouragement for products addressing unmet clinical needs.

At the same time, the "Healthy China 2030" initiative and medical insurance cost-control policies are pushing companies to break away from homogeneous competition and shift toward truly high-barrier, high-value original research and development. Products like AR-dedicated TAVR, with their high technical thresholds and significant clinical implications, align more closely with the direction of high-quality innovation.

Kokai's recent approval sends a clear signal: Chinese medical device companies are increasingly daring to tackle clinical challenges that remain unsolved globally.

In the long race of structural heart disease, the real breakthrough is not necessarily being "the first to make it," but "the first to solve the hardest problem."